A
Antiverse
Using machine learning to optimize and develop the current drug discovery process
About Antiverse
Antiverse is a biotechnology company that operates at the intersection of machine learning and antibody discovery. The company has developed a computational platform that designs and develops antibodies, with a particular focus on challenging drug targets such as G-protein coupled receptors (GPCRs) and ion channels, which are traditionally difficult to address.
Read full description
The core of its business is an AI-augmented drug discovery solution that integrates with next-generation sequencing (NGS) to analyze data from existing lab workloads. This platform is utilized by pharmaceutical companies to accelerate the development of new therapies. The business model appears to be B2B, providing its specialized platform and services to other companies in the pharmaceutical and biotechnology sectors. By enabling the creation of antibodies for difficult targets, the company helps its clients to bring new drugs to market more quickly.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cardiff, United Kingdom
- Employees
- 32
- Open positions
- 2
- Dealroom signal
- 82.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Tech for Biotech and Pharma, AI Drug Discovery, BIA Techbio UK
- Technology
- Artificial Intelligence, Hardware, Deep Tech, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2026 | $9.3M | $37M | Soulmates Ventures · Innovation Investment Capital · Development Bank of Wales · Kadmos Capital | ↗ |
| SEED✓Equity / VC | Oct 2024 | $4.6M | $18M | Kadmos Capital · i&i Biotech Fund · Innospark Ventures · AngelHub | ↗ |
Growth signals
Latest recorded traffic for Antiverse is 4K monthly website visits, up 21.2% over the last three months. Antiverse's team grew 10.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed15 investors entered at this stage
Babraham Bioincubator
Future Planet Capital
Syndicate Room
Wren Capital
Tensor Ventures
Development Bank of Wales
Cambridge Angels
ACF Investors- EPEd Parkinson
Deep Science Ventures
Innospark Ventures
AngelHub
Kadmos Capital
TomorrowScale Ventures
i&i Biotech Fund
Series A3 investors entered at this stage
Soulmates Ventures- ICInnovation Investment Capital
Domino Ventures
Other known investors2 additional known investors
Tech Nation
Martin Drdul
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antiverse on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antiverse’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.